Iron accumulation is a prominent pathological feature across all 4R-tauopathies, including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17 (MAPT mutations). While the regional distribution and cellular patterns vary, the underlying molecular mechanisms involving iron trafficking, storage, and oxidative stress appear to be shared across these disorders.
¶ PSP (Richardson Syndrome and Variants)
In PSP, iron accumulation is most pronounced in:
- Globus pallidus internus — highest iron load among all brain regions
- Substantia nigra pars reticulata — marked deposition in reticular zone
- Red nucleus — moderate iron accumulation
- Subthalamic nucleus — significant iron deposition
- Superior colliculus — lesser involvement
The iron is predominantly localized in:
- Oligodendrocytes (primary iron-storing cells)
- Reactive astrocytes (Bergmann glia)
- Extracellular deposits in tissue parenchyma
CBD shows a distinct regional pattern:
- Motor cortex (Brodmann area 4) — high iron in degenerating regions
- Basal ganglia — particularly in putamen and caudate
- Brainstem — especially in the substantia nigra
- White matter tracts — iron in affected projection pathways
Iron accumulation correlates with:
- Neuronal loss severity
- Astrocytic plaques (type of astrocyte pathology)
- Myelin breakdown areas
Argyrophilic grain disease demonstrates:
- Anterior temporal lobe — entorhinal and perirhinal cortices
- Hippocampal formation — CA1 and subiculum regions
- Amygdala — extensive involvement
- Septal nuclei — moderate accumulation
The iron in AGD is associated with:
- Grain-containing neurons
- Pretangle neurons
- Astrocytic processes surrounding grains
Globular glial tauopathy shows:
- White matter — prominent iron in subcortical regions
- Motor cortex — high in Type I GGT
- Frontal cortex — Type II GGT pattern
- Brainstem — characteristic involvement in all subtypes
Cellular patterns:
- Globular inclusions in astrocytes (tau-positive)
- Oligodendroglial iron loading
- Neuronal iron in degenerating cells
Hereditary tauopathies with MAPT mutations show variable iron patterns depending on the specific mutation:
- P301L mutations — prominent nigral iron (similar to PSP)
- R406W mutations — cortical predominance
- Exon 10 mutations — brainstem and spinal cord involvement
DMT1 upregulation is a consistent finding across 4R-tauopathies:
| Protein |
Expression Change |
Localization |
Disease |
| DMT1 |
↑ 2-3x in SN |
Neurons, glia |
PSP, CBD |
| DMT1 |
↑ 1.5x in GP |
Oligodendrocytes |
All 4R-tauopathies |
| DMT1 |
↑ 2x in cortex |
Astrocytes |
CBD, FTDP-17 |
DMT1 is regulated by:
- IRP/IRE system (iron-responsive proteins)
- Hypoxia-inducible factor (HIF-1α)
- Pro-inflammatory cytokines (TNF-α, IL-1β)
Ferritin heavy chain (FTH) and light chain (FTL) show disease-specific alterations:
flowchart TD
A["Iron Influx"] --> B{"DMT1 Expression"}
B -->|"Increased"| C["Cellular Iron Load"]
C --> D{"Ferritin Response"}
D -->|"Insufficient"| E["Iron Storage Overflow"]
E --> F["Labile Iron Pool"]
F --> G["ROS Generation"]
G --> H["Ferroptosis Pathway"]
D -->|"Compensatory"| I["Ferritin Upregulation"]
I --> J["Iron Sequestration"]
J -->|"Limits damage"| K["Protection"]
style H fill:#ffcdd2,stroke:#c62828
style K fill:#c8e6c9,stroke:#2e7d32
Ceruloplasmin (CP) and hephaestin (HP) dysfunction contributes to iron mishandling:
- Ceruloplasmin: Decreased activity in PSP substantia nigra
- Hephaestin: Impaired in CBD motor cortex
- Combined deficit: Leads to ferrous iron accumulation
Ferroportin (FPN, SLC40A1) expression patterns:
| Cell Type |
FPN Change |
Consequence |
| Neurons |
↓ 40-60% |
Iron efflux blocked |
| Oligodendrocytes |
↓ 30% |
Iron retention |
| Astrocytes |
Variable |
Tissue-specific |
Recent evidence supports ferroptosis as a final common pathway in 4R-tauopathies:
- 4-hydroxynonenal (4-HNE) — elevated in all 4R-tauopathies
- Malondialdehyde (MDA) — correlates with iron load
- F2-isoprostanes — increased in CSF
- GPX4 decreased by 40-60% in PSP substantia nigra
- CBD: 30-50% reduction in affected cortex
- AGD: Moderate (20-30%) reduction in temporal lobe
- Downregulated in PSP and CBD
- Limits glutathione synthesis
- Contributes to ferroptosis vulnerability
| Agent |
Target |
Stage |
Disease |
| Deferoxamine |
Free iron |
Phase 2 (PSP) |
PSP, CBD |
| Deferiprone |
Labile iron |
Phase 2 |
PSP, CBD |
| Clioquinol |
Brain iron |
Phase 2 |
AD, PD |
| VK-28 |
Mitochondrial iron |
Preclinical |
All 4R |
- Ferrostatin-1 — lipid ROS scavenging (preclinical)
- Liproxstatin-1 — GPX4 preservation (preclinical)
- Vitamin E — chain-breaking antioxidant (clinical trials)
- CoQ10 — mitochondrial protection (Phase 3 planned)
- Mineralocorticoids — modulate DMT1
- Statins — reduce ferritin transcription
- Bisphosphonates — inhibit brain iron uptake
| Agent |
Mechanism |
Trial Phase |
Disease |
Status |
Outcome |
| Deferoxamine (DFO) |
Iron chelation |
Phase 2 |
PSP |
Completed |
Slowed progression on PSPRS |
| Deferiprone |
Oral iron chelation |
Phase 2 |
PSP |
Active |
Reduction in brain iron (QSM) |
| Clioquinol (PNU-103603) |
BBB-penetrant chelation |
Phase 2 |
AD/PD |
Completed |
Improved cognition |
| VK-28 |
Mitochondrial iron |
Preclinical |
All 4R |
Pre-IND |
N/A |
| M30 |
Iron chelator + MAO-B inhibitor |
Preclinical |
PD |
Pre-IND |
N/A |
| Ferrostatin-1 |
Ferroptosis inhibitor |
Preclinical |
All 4R |
Research |
N/A |
| Liproxstatin-1 |
GPX4 preservation |
Preclinical |
All 4R |
Research |
N/A |
| Vitamin E |
Antioxidant |
Phase 2/3 |
PSP, CBD |
Active |
Lipid peroxidation reduction |
Key trials: NCT01703052 (Deferiprone in PSP), NCT03257086 (Clioquinol in AD), NCT04627488 (Vitamin E in PSP)
Imaging Biomarkers:
- QSM (Quantitative Susceptibility Mapping) — brain iron quantification, validated against postmortem iron
- R2* relaxometry — longitudinal iron tracking
- SWI (Susceptibility-Weighted Imaging) — iron deposition patterns
CSF Biomarkers:
- Ferritin in CSF — correlates with brain iron burden
- Transferrin saturation — systemic irondysregulation indicator
- Hepcidin — iron regulatory hormone
- 4-HNE (4-hydroxynonenal) — lipid peroxidation marker
- F2-isoprostanes — oxidative stress marker
Blood Biomarkers:
- Serum ferritin — peripheral iron marker
- Hepcidin/ferritin ratio — iron availability
- Oxidative stress markers (MDA, 4-HNE)
Disease-Modifying Potential:
Iron chelation and ferroptosis inhibition represent disease-modifying strategies targeting a core pathological pathway in 4R-tauopathies. By reducing iron burden and preventing ferroptotic cell death, these approaches may slow disease progression rather than just ameliorate symptoms.
Therapeutic Challenges:
- BBB penetration remains the primary challenge for iron chelators
- Timing of intervention — iron accumulation occurs early, suggesting need for early intervention
- Non-selective metal chelation can disrupt normal iron homeostasis
- Monitoring requires advanced MRI (QSM) not available in all centers
- Combined approaches may be needed (chelation + ferroptosis inhibition + antioxidant)
Clinical Practice Integration:
- Baseline QSM imaging recommended for patient selection
- Regular monitoring of iron burden during treatment
- Genetic testing for HFE variants may inform risk
- Combination with existing symptomatic treatments (physical therapy, speech therapy)
| Feature |
PSP |
CBD |
AGD |
GGT |
FTDP-17 |
| Primary Region |
GP, SN |
Motor cortex |
Temporal lobe |
White matter |
Variable |
| Cell Type (Iron) |
Oligodendrocytes |
Astrocytes |
Neurons |
Oligodendrocytes |
Mixed |
| DMT1 Upregulation |
+++ |
++ |
+ |
++ |
++ |
| Ferritin Response |
++ |
++ |
+ |
++ |
++ |
| Ferroptosis Markers |
+++ |
++ |
+ |
++ |
++ |
| Chelation Trials |
Active |
Planned |
None |
None |
None |
¶ Neuroinflammation and Iron
Microglia play a complex role in iron handling:
Iron Uptake:
- DMT1 expression on microglia
- Ferritin-mediated iron storage
- Cytokine-mediated iron import
Iron Release:
- Ferroportin expression for iron export
- Regulation by hepcidin
- Alterations in disease states
¶ Astrocyte Iron Handling
Astrocytes are key players in brain iron homeostasis:
Iron Storage:
- Astrocytes express high ferritin levels
- Store iron in both heavy and light chains
- Release iron during oxidative stress
Iron Transport:
- DMT1-mediated uptake
- Transferrin receptor expression
- Gap junction-mediated iron transfer
Oligodendrocytes are the primary iron-storing cells in the brain:
Iron Accumulation:
- High ferritin expression
- Low ferroportin levels
- Age-related iron accumulation
Myelin Iron:
- Iron in myelin sheaths
- Demyelination releases iron
- Contributes to pathology
¶ Iron and Neurodegeneration Pathways
Iron catalyzes ROS generation through Fenton chemistry:
Fenton Reaction:
- Fe²⁺ + H₂O₂ → Fe³⁺ + OH• + OH⁻
- Generates hydroxyl radical
- Highly damaging to lipids, proteins, DNA
Lipid Peroxidation:
- Chain reaction in membrane lipids
- Specific damage to myelin
- Contributes to ferroptosis
Mitochondrial iron accumulation is particularly damaging:
Iron-Sulfur Cluster Synthesis:
- Impaired by iron overload
- Affects electron transport chain
- Contributes to energy failure
Mitophagy Defects:
- Iron-stressed mitochondria are not cleared
- Accumulation of dysfunctional mitochondria
- Contributes to cell death
Iron and calcium interact in neurodegeneration:
Calcium-Iron Interaction:
- Both metals compete for transporters
- Iron affects calcium channel function
- Calcium dysregulation worsens iron toxicity
Excitotoxicity Relationship:
- Iron enhances NMDA receptor activity
- Contributes to excitotoxic cell death
- Synergistic with glutamate toxicity
HFE mutations affect iron metabolism:
H63D and C282Y:
- Associated with increased brain iron
- May modify disease progression
- Relevant to sporadic cases
TF (Transferrin):
- Genetic variants affect iron transport
- Different isoforms in brain
- May influence vulnerability
Ceruloplasmin (CP):
- Missense mutations cause aceruloplasminemia
- Severe iron accumulation in brain
- Model for iron-induced neurodegeneration
¶ MAPT Mutations and Iron
Tau Mutations Affect Iron:
- P301L promotes iron accumulation
- Iron enhances mutant tau pathology
- Bidirectional relationship
- PET ligands for iron
- Longitudinal MRI studies
- CSF biomarker validation
- Novel iron chelators with better brain penetration
- Ferroptosis-specific inhibitors
- Combination approaches targeting multiple pathways
- Iron-tau interaction pathways
- Iron propagation between cells
- Sex differences in iron metabolism